Edition:
India

Mesoblast Ltd (MESO.OQ)

MESO.OQ on NASDAQ Stock Exchange Global Select Market

5.95USD
17 Jan 2018
Change (% chg)

$0.12 (+2.06%)
Prev Close
$5.83
Open
$5.90
Day's High
$5.96
Day's Low
$5.85
Volume
7,227
Avg. Vol
9,725
52-wk High
$12.50
52-wk Low
$4.82

Select another date:

Thu, Dec 21 2017

FDA to fast track Mesoblast's cell therapy for heart failure

Australian drug developer Mesoblast Ltd said on Thursday the U.S. Food and Drug Administration would fast track the review of its cell therapy treatment for heart failure patients under a new designation rolled out last December.

FDA to fast track Mesoblast's cell therapy for heart failure

Dec 21 Australian drug developer Mesoblast Ltd said on Thursday the U.S. Food and Drug Administration would fast track the review of its cell therapy treatment for heart failure patients under a new designation rolled out last December.

BRIEF-Mesoblast Gets Regenerative Medicine Advanced Therapy Designation From U.S. FDA​

* ‍U.S. FDA GRANTED REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION FOR ITS MESENCHYMAL PRECURSOR CELL THERAPY ​ Source text for Eikon: Further company coverage:

BRIEF-Mesoblast's Phase 3 Trial In Children With Acute Graft Versus Host Disease Completes Enrollment

* MESOBLAST'S PHASE 3 TRIAL IN CHILDREN WITH ACUTE GRAFT VERSUS HOST DISEASE COMPLETES ENROLLMENT

BRIEF-Mesoblast Says Granted Tigenix Access To Certain Of Its Patents

* ‍HAS GRANTED TIGENIX EXCLUSIVE ACCESS TO CERTAIN OF ITS PATENTS TO SUPPORT GLOBAL COMMERCIALIZATION OF STEM CELL PRODUCT CX601​ Source text for Eikon: Further company coverage:

BRIEF-Tigenix Nv - Mesoblast Grants Access To Patents To Support Commercialization Of Adipose-Derived Mesenchymal Stem Cell Product Cx601 For Treatment Of Fistulae​

* - MESOBLAST GRANTS ACCESS TO PATENTS TO SUPPORT COMMERCIALIZATION OF ADIPOSE-DERIVED MESENCHYMAL STEM CELL PRODUCT CX601 FOR TREATMENT OF FISTULAE​

BRIEF-MESOBLAST PHASE 2 TRIAL RESULTS SHOW DURABLE EFFECTS IN ARTHRITIS PATIENTS

* MESOBLAST PHASE 2 TRIAL RESULTS SHOW EARLY AND DURABLE EFFECTS OF SINGLE MESENCHYMAL PRECURSOR CELL INFUSION IN BIOLOGIC REFRACTORY RHEUMATOID ARTHRITIS PATIENTS

BRIEF-Clinical trial of Mesoblast’S cell therapy in end-stage heart failure patients completes enrollment

* Clinical trial of Mesoblast’S cell therapy in end-stage heart failure patients completes enrollment Source text for Eikon: Further company coverage:

BRIEF-Mesoblast posts FY loss attributable of $76.8 mln

* FY loss attributable to owners of co $76.8 million versus loss of $4.1 million Source text for Eikon: Further company coverage:

BRIEF-Mesoblast completes institutional entitlement offer for capital raise

* Completes institutional entitlement offer for fully underwritten A$50.7 million capital raise

Select another date: